Proton Pump Inhibitors and Cancer Risk
Investigators evaluate cancer risk tied to extended acid suppression therapy.
-
By
-
Kathryn Wighton
-
February 19, 2026
-
Clinical Scorecard: Proton Pump Inhibitors and Cancer Risk
At a Glance
| Category | Detail |
|---|
| Condition | Gastric Non-Cardia Adenocarcinoma |
| Key Mechanisms | Long-term proton pump inhibitor use and its association with cancer risk. |
| Target Population | Patients with a history of proton pump inhibitor use. |
| Care Setting | Multinational, population-based case-control study. |
Key Highlights
- No measurable increase in gastric non-cardia adenocarcinoma risk with long-term proton pump inhibitor use.
- Study included 17,232 cases and 172,297 matched controls from Nordic countries.
- Adjustment for various confounding factors showed proton pump inhibitor use comparable to nonuse in cancer risk.
- Sensitivity analyses indicated increased risk estimates under specific conditions.
- Study limitations include potential residual confounding and observational design.
Guideline-Based Recommendations
Diagnosis
- Consider long-term proton pump inhibitor use in the context of gastric cancer risk assessment.
Management
- Monitor patients on long-term proton pump inhibitors for other risk factors of gastric cancer.
Monitoring & Follow-up
- Regular assessment of patient history and potential confounding factors.
Risks
- Potential for residual confounding despite extensive multivariable adjustment.
Patient & Prescribing Data
Patients with gastric non-cardia adenocarcinoma and matched controls.
Long-term proton pump inhibitor use does not significantly increase cancer risk.
Clinical Best Practices
- Utilize nationwide registry data to minimize recall and selection bias.
- Adjust for confounding factors when assessing cancer risk in patients using proton pump inhibitors.
References
